Close Menu

NEW YORK – The GenomeWeb Index rose nearly 13 percent in July, as investors once again sought to reward companies that seemed to be making significant developments with their SARS-CoV-2 diagnostics.

The index outperformed the Dow Jones Industrial Average, the Nasdaq, and the Nasdaq Biotechnology Index, which rose 2 percent, 7 percent, and nearly 2 percent, respectively. Individual stock performances in the GenomeWeb Index were overwhelmingly positive in July, as 28 of the 32 stocks saw gains and only four saw losses.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Reuters reports that Germany is seeking to sequence 5 percent of patient samples that test positive for SARS-CoV-2.

23andMe and Medscape say primary care physicians are increasingly more comfortable with discussing direct-to-consumer genetic testing results.

The publisher of the Science family of journals will allow some authors to place peer-reviewed versions of their papers into publicly accessible repositories.

In Science this week: analysis of genome-wide association studies of chronic kidney disease, and more.